GoldiloxBio

What it does

GoldiloxBio is an innovative lifetech company focused on transforming drug discovery through the development of advanced assays that accurately predict human toxicities. By integrating hardware, software, and biomaterials, the company recreates critical aspects of human physiology in vitro to provide drug developers with predictive, human-relevant data. This approach addresses the limitations of traditional animal models, offering faster, more cost-effective, and reliable insights that help de-risk drug candidates before clinical trials. GoldiloxBio’s platform aims to accelerate development timelines and improve clinical success rates by delivering actionable information on drug safety. The company’s initial service focuses on cardiotoxicity testing, with ongoing efforts to enhance data interpretation through machine learning. GoldiloxBio’s contributions represent a significant advancement in preclinical testing, supporting innovation in drug development and reducing reliance on less predictive models.